Is Osimertinib Better Alone or With Chemotherapy in NSCLC? :

A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting.

Related Keywords

Boston , Massachusetts , United States , Illinois , University Of Chicago , Chicago , Dana Farber Cancer Institute , San Diego , California , American , Marina Garassino , Clinical Research Annual Meeting , American Association , Astrazeneca , Drug Administration , American Association For Clinical Research Annual , Pasi Janne , Lung Cancer , Ung Carcinoma , Ancer Of The Lung , Non Small Cell Lung Cancer , Nsclc , Genomics Genomic Medicine , Small Cell Lung Cancer , At Cell Lung Cancer , Clc , Cancer , Alignant Neoplasia , Arcinoma , Alignant Neoplasm , Chemotherapy , Toxicology , Toxicity , Poisoning , Toxins , Malignant Head And Neck Neoplasm , Head And Neck Cancer , Ead And Neck Cancer Hnc , Metastasis ,